September 2016, Volume 2, Issue 9

September 2016

Volume 2, Issue 9

This issue discusses transitioning pediatric patients to the adult system, features an interview between ASH and ABIM about MOC, and provides coverage from the ASH Workshop on Genome Editing.

Table of Contents

September 2016

The Decline and Fall of Cytotoxic Chemotherapy

Thursday, September 1st, 2016
Here, Dr. Stewart gives his take on whether cytotoxic chemotherapy should be declared a thing of the past. As ward rounds ended last Saturday, a...

Top Ten Tips and Tricks for Treatment Adherence and Side Effect Management

Thursday, September 1st, 2016
It’s 8 a.m. on a beautiful summer morning. The sun is shining and all seems right with the world. Then, as I approach my...

How to treat a young patient with a rare composite lymphoma diagnosis?

Thursday, September 1st, 2016
Here's how readers responded to a You Make the Call Question about a young patient with a rare composite lymphoma diagnosis. Disclaimer: ASH does not...

September 2016

Award recipients, Ask the Hematologist Compendium, and more

Thursday, September 1st, 2016
ASH Announces Prestigious Honorific Awards for 2016 Each year, the Society recognizes outstanding hematologists who have made significant contributions to the field with the following...

Remembering Alfred G. Knudson Jr., MD, PhD and James G. White, MD, ASH Bridge...

Thursday, September 1st, 2016
Alfred G. Knudson Jr., MD, PhD (1922 – 2016) Alfred G. Knudson Jr., MD, PhD, former president and scientific director of the Fox Chase Cancer...

September 2016

Dr. Kass with the cast of “Front Page Flo”

The Music Man: Lawrence Kass, MD

Thursday, September 1st, 2016
When did your interest in composing music start? I come from a musical background. Both of my parents were musicians. My father was a trained...
Dr. Michaelis spending time with her dog.

Pulling Back the Curtain: Laura C. Michaelis, MD

Thursday, September 1st, 2016
What was your first job? My very first job was babysitting in high school; I used to have a pretty robust babysitting business, with five...

Revisiting Maintenance of Certification: Updates from ASH and ABIM Interview with Marc S....

Thursday, September 1st, 2016
In 2015, the American Board of Internal Medicine (ABIM) issued a statement in response to numerous criticisms from diplomates and specialty societies, including the...

Coming of Age

Thursday, September 1st, 2016
The transition and transfer of patients with hematologic conditions from pediatric to adult care often comes at a crucial time. The years spent transitioning from...

September 2016

What should I prescribe a young patient with a rare composite lymphoma diagnosis?

Thursday, September 1st, 2016
This month, Jane Winter, MD, talks about how she would treat a young patient with a rare composite lymphoma diagnosis. I have an 18-year-old female patient...

September 2016

Post-Transplant Survival Rates Are Similar Between Lymphoma Patients With Haploidentical Related and HLA-Matched Sibling...

Thursday, September 1st, 2016
Allogeneic hematopoietic cell transplantation (alloHCT) is the only potentially curative treatment option for patients with high-risk relapsed or refractory lymphoma, but the lack of...
WIB_icon

Long-Term Follow-Up Shows Arsenic Trioxide Plus All-Trans Retinoic Acid Extends Survival for Acute Promyelocytic...

Thursday, September 1st, 2016
Results from a 12-year follow-up study of all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) confirm that the ATRA/ATO combination leads to longer survival,...
WIB_icon

Lenalidomide Plus Bendamustine and Rituximab Led to Increased Activity, Increased Toxicity in Older Patients...

Thursday, September 1st, 2016
Mantle cell lymphoma (MCL) is associated with a median overall survival (OS) of five years, and for elderly patients – who comprise a majority...

FDA Issues New Draft Guidance for the “Appearance” of Conflicts of Interest

Thursday, September 1st, 2016
The U.S. Food and Drug Administration (FDA) issued draft guidance for the appearance of conflicts of interest with regard to serving on one of...

National Institutes of Health Awards $55 Million to Launch Million-Person Precision Medicine Study

Thursday, September 1st, 2016
The National Institutes of Health (NIH) awarded $55 million in funding for fiscal year 2016 to launch the Cohort Program of President Obama’s Precision...

Midostaurin: A Promising New Option for Patients With Advanced Systemic Mastocytosis

Thursday, September 1st, 2016
Advanced systemic mastocytosis (SM) is a rare myeloproliferative neoplasm associated with poor prognosis and a lack of effective treatment options. The oral, multitarget protein...
WIB_icon

Multirefractory ITP Associated With Higher Morbidity and Mortality Than “Typical” ITP

Thursday, September 1st, 2016
In a multicenter, retrospective, cohort study, Matthieu Mahévas, MD, PhD, of the National Reference Center for Adult Auto-Immune Cytopenias at Hôpital Henri Mondor, in...

FDA Grants Breakthrough Therapy Designations to Two Therapies for Acute and Chronic Graft-Versus-Host Disease

Thursday, September 1st, 2016
The FDA granted breakthrough therapy designation to ruxolitinib for the treatment of patients with acute graft-versus-host disease (aGVHD), a condition that has no approved...

PCORI Approves $6.5 Million Funding for Anticoagulant Research

Thursday, September 1st, 2016
The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors announced it will contribute $6.5 million to fund two studies that will examine the effectiveness...

FDA Grants Fast Track Designation to Plasminogen Drug

Thursday, September 1st, 2016
The FDA has granted “Fast Track” designation to a plasminogen drug candidate for the treatment of patients with congenital plasminogen deficiency. The investigational plasminogen...

CMS Posts Open Payments Financial Data for 2015

Thursday, September 1st, 2016
The Centers for Medicare & Medicaid Services (CMS) posted the Open Payments (or “Sunshine Act”) data for program year 2015, along with newly submitted...

National Hemophilia Foundation Releases New Clinical Practice Guideline on Care Models for Hemophilia Management

Thursday, September 1st, 2016
The National Hemophilia Foundation (NHF) and McMaster University recently announced the publication of an evidence-based clinical practice guideline on Care Models for Hemophilia Management....
WIB_icon

Study Identifies Germline Variants That Predispose Patients to Developing Myeloproliferative Neoplasms

Thursday, September 1st, 2016
Though the JAK2 V617F mutation is present in the majority of patients with myeloproliferative neoplasms (MPNs) like polycythemia vera (PV) and primary myelofibrosis (PMF),...

FDA Grants Breakthrough Therapy Designation for Daratumumab for the Treatment of Multiple Myeloma

Thursday, September 1st, 2016
The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for...

Biomarker-Directed Trial for AML or MDS, Safety and Efficacy of BMN 270 for Hemophilia,...

Thursday, September 1st, 2016
LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE) (NCT02562443) Study...

What is the Optimal Management of Upper-Extremity Superficial and Deep Vein Thrombosis?

Thursday, September 1st, 2016
The incidence of upper extremity deep vein thrombosis (UEDVT) is increasing, most commonly due to more widespread use of central venous catheters (CVCs), but...

Sickle Cell Trait Not Associated With Increased Risk of Death in African-American U.S. Army...

Thursday, September 1st, 2016
Research has suggested that sickle cell trait (SCT) contributes to elevated risks of exertional rhabdomyolysis (muscle deterioration due to extreme physical exertion) and death,...
WIB_icon

Finding a Clinical, Molecular Risk Model That Predicts Disease Progression in Follicular Lymphoma

Thursday, September 1st, 2016
Though post-treatment surrogate endpoints, such as disease progression within 24 months (POD24; defined as relapse or progression of FL within 24 months of first-line...

September 2016

Harnessing the Power of Gene Editing

Thursday, September 1st, 2016
For years, scientists have been manipulating genes in animal and human cells to gain a better understanding of how genomes work, with an eye...

SHARE